

CLPTM1L Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP16233b**Specification**

CLPTM1L Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [Q96KA5](#)**CLPTM1L Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 81037**Other Names**

Cleft lip and palate transmembrane protein 1-like protein, CLPTM1-like protein, Cisplatin resistance-related protein 9, CRR9p, CLPTM1L, CRR9

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CLPTM1L Antibody (C-term) Blocking Peptide - Protein Information**Name** CLPTM1L**Synonyms** CRR9**Function**

Scramblase that mediates the translocation of glucosaminylphosphatidylinositol (alpha-D-GlcN-(1-6)-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol, GlcN-PI) across the endoplasmic reticulum (ER) membrane, from the cytosolic leaflet to the luminal leaflet of the ER membrane, where it participates in the biosynthesis of glycosylphosphatidylinositol (GPI) (PubMed:35344438). GPI is a lipid glycoconjugate involved in post-translational modification of proteins (PubMed:35344438). Can also translocate 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) (phosphatidylinositol or PI), as well as several other phospholipids (1,2-diacyl-sn-glycero-3-phosphocholine, 1,2-diacyl-sn-glycero-3-phosphoethanolamine), and N-acetylglucosaminylphosphatidylinositol (GlcNAc-PI) in vitro (PubMed:35344438).

Cellular Location

Endoplasmic reticulum membrane; Multi-pass membrane protein

Tissue Location

Ubiquitously expressed.

CLPTM1L Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CLPTM1L Antibody (C-term) Blocking Peptide - Images**CLPTM1L Antibody (C-term) Blocking Peptide - Background**

CLPTM1L enhances cisplatin-mediated apoptosis, when overexpressed.

CLPTM1L Antibody (C-term) Blocking Peptide - References

Liu, Z., et al. Carcinogenesis 31(11):1977-1981(2010)Hsiung, C.A., et al. PLoS Genet. 6 (8) (2010)
:Truong, T., et al. J. Natl. Cancer Inst. 102(13):959-971(2010)Pooley, K.A., et al. Cancer Epidemiol.
Biomarkers Prev. 19(7):1862-1865(2010)Turnbull, C., et al. Nat. Genet. 42(7):604-607(2010)